(Q34499681)

2 August 2017

title

What went wrong in the natalizumab trials? (English)

1 reference

2 August 2017

Annette Langer-Gould

1

1 reference

2 August 2017

Lawrence Steinman

series ordinal

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

2 August 2017

1 reference

2 August 2017

volume

367

1 reference

2 August 2017

issue

9512

1 reference

2 August 2017

page(s)

708-710

1 reference

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968279-2

7 January 2021

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968279-2

7 January 2021

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968279-2

7 January 2021

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968279-2

7 January 2021

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968279-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968279-2

7 January 2021

Longitudinal disability curves for predicting the course of relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968279-2

7 January 2021

Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968279-2

7 January 2021

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968279-2

7 January 2021

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968279-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968279-2

7 January 2021

Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968279-2

7 January 2021

Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968279-2

7 January 2021

A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968279-2

7 January 2021

Screening for disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968279-2

7 January 2021

Measures of physical and cognitive function and work status among individuals with multiple sclerosis: a review of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968279-2

7 January 2021

The association between cognitive impairment and physical disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968279-2

7 January 2021

Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968279-2

7 January 2021

Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968279-2

7 January 2021

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968279-2

7 January 2021

10.1016/S0140-6736(06)68279-2

Identifiers

DOI

1 reference

2 August 2017

1 reference